On Air Now

Current Show

Jerry Bader   9:00 AM - 11:00 AM

Call The Jerry Bader Show at 1-888-455-1360

Show Info »

Upcoming Shows

Program Schedule »

Listen

Listen Live Now » 550 AM Wausau, WI 99.9 FM Stevens Point, WI

Weather

Current Conditions(Wausau,WI 54403)

More Weather »
65° Feels Like: 65°
Wind: W 6 mph Past 24 hrs - Precip: 0.01”
Current Radar for Zip

Today

Isolated Thunderstorms 79°

Tonight

Mostly Clear 56°

Tomorrow

Scattered Thunderstorms 80°

Alerts

Breaking News

BREAKING NEWS / URGENT: The State Supreme Court upholds Act 10, Voter ID, and the state's domestic partnership registry

MADISON, Wis (WSAU)  - The Wisconsin State Supreme Court upheld Act 10, the state law that limits the collective bargaining rights of state employees. The law from three years ago sparked protests at the state capital and led to the recall attempt against Governor Scott Walker. The court's ruling in favor of Act 10 was 5-2. Justice Michael Gableman wrote the lead opinion, which was also signed by Justices David Prosser, Pat Roggensack and Annette Ziegler. Justice Patrick Crooks concurre...

Read More »

GSK taps UK firm for 'beyond antibodies' drug technology

By P.J. Huffstutter

LONDON (Reuters) - GlaxoSmithKline plans to exploit new technology from private British biotech company Immunocore to develop next-generation drugs against cancer that fight tumors in ways antibody-based drugs cannot.

Britain's biggest pharmaceuticals group will pay 142 million pounds ($212 million) in pre-clinical milestone payments for access to the Oxford-based company's work on multiple drug targets, the two partners said on Tuesday.

Immunocore will also get up to 200 million pounds for each product that finally reaches the market, plus up to double-digit percentage royalties on any sales.

The tie-up with GSK is the second validation of Immunocore's work by a big pharmaceutical company, following a similar deal with Roche's Genentech unit last month.

Immunocore's technology relies on a new type of medicines it calls "ImmTACs." These drugs exploit the power of T cell receptors -- a part of the immune system -- to recognize changes that occur inside cells during cancer or viral infection. ImmTACs then activate the immune system to kill targeted cells.

Traditional antibody-based therapies only recognize changes on the surface of cells. Laurent Jespers, head of innovation at GSK's biopharmaceuticals unit, said ImmTACs offered "a tremendous opportunity" in treating cancer.

The most advanced ImmTAC drug, IMCgp100 for the treatment of melanoma, is currently in early Phase I/II clinical trials.

Comments